SECTM1-based CAR T cells enriched with CD7-low/negative subsets exhibit efficacy in CD7-positive malignancies

CD7 has been found to be a promising chimeric antigen receptor (CAR) T cell target in several clinical trials. However, its expression on normal T cells poses additional challenges in CD7-directed CAR therapy, such as complete fratricide, contamination with malignant cells, and immune suppression du...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wenwen, Ma, Haiyan, Yang, Dong, Sun, Bin, Tang, Jie, Zhu, Yongjie, Chen, Xinchuan, Huang, Xiaoou, Liu, Jiazhuo, Hu, Zhengfei, Liu, Ting, Zou, Liqun, Zhao, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320215/
https://www.ncbi.nlm.nih.gov/pubmed/36848638
http://dx.doi.org/10.1182/bloodadvances.2022008402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320215/
https://www.ncbi.nlm.nih.gov/pubmed/36848638
http://dx.doi.org/10.1182/bloodadvances.2022008402

Ejemplares similares